Developer docs
API playgroundTry for free, no card

Search company profiles

Aetion

Full company profile

uuid0000hfg

Namestring
Aetion
Legal namestring
Aetion, Inc.
Websiteurl
aetion.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Aetion is a New York-based healthcare technology company founded in 2013 that provides real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies. Its core product is the Aetion Evidence Platform, a proprietary system that analyzes real-world data (RWD) to support drug development, clinical trial analysis, personalized medicine, and regulatory submissions for major biopharma customers worldwide. The platform leverages generative AI built on Amazon Bedrock to translate scientific intent into analytical results, and in August 2025 the company launched aetion activate, an accelerated RWD analysis module. Aetion operates a subscription-based SaaS revenue model distributed through direct enterprise sales to biopharma customers, with the Evidence Platform also made available on AWS Marketplace in March 2025 to broaden cloud-native procurement.

Aetion's customer base is concentrated in major biopharma enterprises, and the company reported near-100% customer renewals with revenue nearly doubling in the year preceding its May 2021 $110 million Series C led by Warburg Pincus. In February 2025, NEC Orchestrating Future Fund made a strategic investment and began collaboration discussions to apply Japanese electronic health records to drug development. In May 2025, Datavant announced its acquisition of Aetion to combine Aetion's RWE capabilities with Datavant's data discovery, linkage, privacy, and analytics infrastructure into an end-to-end RWE platform. Following the acquisition, Aetion operates as part of Datavant's life sciences offerings and is no longer an independent entity.

Short descriptiontext

Aetion provides a proprietary Evidence Platform for real-world evidence generation, serving major biopharma companies in drug development, clinical trials, and regulatory submissions. The platform uses generative AI on AWS Bedrock and was acquired by Datavant in May 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
real-world evidence platform, biopharma analytics software, healthcare data analytics, clinical evidence generation, outcomes-based analytics
Industry2 codes
PRIMARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers5132
  • Other Scientific and Technical Consulting Services541690
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Healthcare Analytics Software
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Evidence Platform SaaS Subscription
TypeSubscription Recurring
Description

Aetion generates revenue through its Evidence Platform which supports real-world evidence generation for biopharma customers. The company showed nearly 100% customer renewals and nearly doubled revenue in the year prior to its 2021 Series C, indicating a recurring subscription model.

ow.ly
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1Aetion Evidence Platform
Description

Platform supporting real-world evidence generation used by major biopharma companies worldwide

ow.ly
+1 more record
Core offering1 text field

Aetion develops and sells the Aetion Evidence Platform, a real-world evidence (RWE) analytics software platform used by major biopharma companies to analyze real-world data for drug development, clinical trial design, regulatory submissions, and personalized medicine. The platform leverages generative AI on Amazon Bedrock to translate scientific intent into analytical results, and is sold as enterprise SaaS with an option to procure through AWS Marketplace.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Nearly 100% customer renewal rate in the year prior to 2021 Series C
+1 more record
Product overview1 text field

Aetion offers a platform-plus-modules architecture centered on its Evidence Platform® for real-world evidence generation. The core platform processes and analyzes real-world data from diverse sources, while aetion activate (launched August 2025) provides accelerated analysis capabilities. The company leverages generative AI via Amazon Bedrock to translate scientific intent into results, serving biopharma companies, healthcare providers, and regulatory bodies seeking to improve drug development efficiency and advance personalized medicine.

Product and service2 records
1Aetion Evidence Platform
CategoryReal-World Evidence Analytics Platform
Description

Software platform that enables life sciences companies to analyze real-world data for drug development, clinical trials, regulatory submissions, and personalized medicine, using generative AI to translate scientific intent into analytical results.

2aetion activate
CategoryReal-World Data Analytics Acceleration
Description

Product that accelerates real-world data analysis for pharmaceutical and life sciences companies, designed to generate real-world evidence insights more efficiently from real-world datasets.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-05-18
Description

Datavant announced its acquisition of Aetion in May 2025, aimed at enhancing Datavant's capabilities for life sciences and creating an end-to-end RWE platform. The acquisition combines Aetion's RWE solutions with Datavant's data discovery, linkage, privacy, and advanced analysis capabilities. Following the acquisition, Aetion operates as part of Datavant's platform ecosystem.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-02-26
Description

Aetion leverages Amazon Bedrock (AWS's generative AI service) to power its Evidence Platform. In March 2025, Aetion also launched the availability of its Evidence Platform in the AWS Marketplace. AWS provides the cloud infrastructure and AI capabilities underlying Aetion's platform, enabling generative AI-driven translation of scientific intent into results.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Evidera is a dedicated real-world evidence and health economics consulting business serving biopharma. It is directly comparable to Aetion because both provide RWE generation and outcomes analytics for life sciences customers, often competing for the same budget line within biopharma R&D and HEOR teams.

TypeEmerging player
Description

ConcertAI provides AI-powered real-world evidence and data solutions with a focus on oncology and specialty therapeutics. It is comparable to Aetion because both serve biopharma with RWE analytics derived from clinical real-world data, competing for similar evidence-generation engagements with major pharma.

TypeBroad incumbent
Description

ICON (following its PRA Health Sciences acquisition) is a top global CRO with established real-world evidence and outcomes research capabilities. It is comparable to Aetion because both deliver RWE services to biopharma for clinical and post-marketing evidence generation, though ICON operates a much broader CRO service portfolio.

TypeEmerging player
Description

Health Catalyst provides healthcare data and analytics infrastructure, including life sciences solutions leveraging clinical and claims data. It is comparable to Aetion because both turn real-world clinical data into analytics products for healthcare stakeholders, though Health Catalyst is more provider-system-anchored while Aetion is biopharma-focused.

5Tempus Labs
TypeEmerging player
Description

Tempus combines multimodal real-world data (omics, EHR, imaging) with AI to support biopharma research and clinical decision-making. It is comparable to Aetion because both build AI-enabled RWE platforms serving biopharma drug development, though Tempus is more focused on oncology and molecular data depth.

TypeEmerging player
Description

OM1 is a specialty real-world evidence and outcomes analytics company focused on chronic and specialty disease areas. It is comparable to Aetion because both deliver RWE analytics to biopharma and payers, with similar specialty-therapeutic-area orientation and emphasis on regulatory-grade evidence generation.

TypeBroad incumbent
Description

IQVIA is the largest global CRO and a leading provider of real-world evidence solutions to biopharma. It is comparable to Aetion because both serve major biopharma customers with RWE analytics, though IQVIA operates at vastly greater scale and offers a much broader portfolio spanning clinical trials, commercial, and real-world data.

TypeDirect peer
Description

Flatiron Health is a direct competitor in real-world evidence, focused on oncology EHR-derived data and analytics for biopharma and providers. It is highly comparable to Aetion because both build RWE platforms from real-world clinical data to support drug development and regulatory submissions for life sciences customers.

TypeDirect peer
Description

TriNetX operates a global health research network and RWE platform for clinical trial design, cohort identification, and real-world evidence studies. It is directly comparable to Aetion because both sell RWE platforms to biopharma for protocol design, regulatory evidence, and clinical development decisions using federated real-world data.

TypeBroad incumbent
Description

Optum Life Sciences, part of UnitedHealth Group, provides real-world data and evidence solutions to biopharma leveraging one of the largest U.S. claims and EHR data assets. It is comparable to Aetion because both deliver RWE analytics for biopharma, though Optum's data scale and integrated payer-provider footprint are far larger.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aetion

Healthcare Analytics Softwareaetion.com

Aetion provides a proprietary Evidence Platform for real-world evidence generation, serving major biopharma companies in drug development, clinical trials, and regulatory submissions. The platform uses generative AI on AWS Bedrock and was acquired by Datavant in May 2025.

What Aetion does

Aetion is a New York-based healthcare technology company founded in 2013 that provides real-world evidence (RWE) and outcomes-based analytics solutions to life sciences companies. Its core product is the Aetion Evidence Platform, a proprietary system that analyzes real-world data (RWD) to support drug development, clinical trial analysis, personalized medicine, and regulatory submissions for major biopharma customers worldwide. The platform leverages generative AI built on Amazon Bedrock to translate scientific intent into analytical results, and in August 2025 the company launched aetion activate, an accelerated RWD analysis module. Aetion operates a subscription-based SaaS revenue model distributed through direct enterprise sales to biopharma customers, with the Evidence Platform also made available on AWS Marketplace in March 2025 to broaden cloud-native procurement.

Aetion's customer base is concentrated in major biopharma enterprises, and the company reported near-100% customer renewals with revenue nearly doubling in the year preceding its May 2021 $110 million Series C led by Warburg Pincus. In February 2025, NEC Orchestrating Future Fund made a strategic investment and began collaboration discussions to apply Japanese electronic health records to drug development. In May 2025, Datavant announced its acquisition of Aetion to combine Aetion's RWE capabilities with Datavant's data discovery, linkage, privacy, and analytics infrastructure into an end-to-end RWE platform. Following the acquisition, Aetion operates as part of Datavant's life sciences offerings and is no longer an independent entity.

Aetion firmographics

Firmographics
Name
Aetion
Legal name
Aetion, Inc.
Website
https://aetion.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
51–100 employees
Short description
Aetion provides a proprietary Evidence Platform for real-world evidence generation, serving major biopharma companies in drug development, clinical trials, and regulatory submissions. The platform uses generative AI on AWS Bedrock and was acquired by Datavant in May 2025.
Ownership category
akta.pro rank

Aetion industry classification

Industry
Product category
Healthcare Analytics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYBPAHALAN
Healthcare Outcomes & Real-World Evidence (RWE) Analytics
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Real-world evidence platform
  • Biopharma analytics software
  • Healthcare data analytics
  • Clinical evidence generation
  • Outcomes-based analytics

Where Aetion is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aetion business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Evidence Platform SaaS Subscription: Aetion generates revenue through its Evidence Platform which supports real-world evidence generation for biopharma customers. The company showed nearly 100% customer renewals and nearly doubled revenue in the year prior to its 2021 Series C, indicating a recurring subscription model.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels3 records

Aetion product offering

Product offering

Core offering

Aetion develops and sells the Aetion Evidence Platform, a real-world evidence (RWE) analytics software platform used by major biopharma companies to analyze real-world data for drug development, clinical trial design, regulatory submissions, and personalized medicine. The platform leverages generative AI on Amazon Bedrock to translate scientific intent into analytical results, and is sold as enterprise SaaS with an option to procure through AWS Marketplace.

Product overview

Aetion offers a platform-plus-modules architecture centered on its Evidence Platform® for real-world evidence generation. The core platform processes and analyzes real-world data from diverse sources, while aetion activate (launched August 2025) provides accelerated analysis capabilities. The company leverages generative AI via Amazon Bedrock to translate scientific intent into results, serving biopharma companies, healthcare providers, and regulatory bodies seeking to improve drug development efficiency and advance personalized medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • Aetion Evidence Platform: Platform supporting real-world evidence generation used by major biopharma companies worldwide
  • aetion activate

Products and services

  • Aetion Evidence Platform Software platform that enables life sciences companies to analyze real-world data for drug development, clinical trials, regulatory submissions, and personalized medicine, using generative AI to translate scientific intent into analytical results.
  • aetion activate Product that accelerates real-world data analysis for pharmaceutical and life sciences companies, designed to generate real-world evidence insights more efficiently from real-world datasets.

Quantifiable outcome

  • Nearly 100% customer renewal rate in the year prior to 2021 Series C
  • +1 more outcomes

Companies that use Aetion

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Aetion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Aetion partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered major and core.

  • DatavantmajorStrategic or Co-development Partner · 18 May 2025Datavant announced its acquisition of Aetion in May 2025, aimed at enhancing Datavant's capabilities for life sciences and creating an end-to-end RWE platform. The acquisition combines Aetion's RWE solutions with Datavant's data discovery, linkage, privacy, and advanced analysis capabilities. Following the acquisition, Aetion operates as part of Datavant's platform ecosystem.
  • Amazon Web Services (AWS)coreTechnology or Integration · 26 February 2025Aetion leverages Amazon Bedrock (AWS's generative AI service) to power its Evidence Platform. In March 2025, Aetion also launched the availability of its Evidence Platform in the AWS Marketplace. AWS provides the cloud infrastructure and AI capabilities underlying Aetion's platform, enabling generative AI-driven translation of scientific intent into results.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Aetion competitors and assessment

Company assessment

Direct peers

  • Evidera (PPD / Thermo Fisher Scientific): Evidera is a dedicated real-world evidence and health economics consulting business serving biopharma. It is directly comparable to Aetion because both provide RWE generation and outcomes analytics for life sciences customers, often competing for the same budget line within biopharma R&D and HEOR teams.
  • Flatiron Health: Flatiron Health is a direct competitor in real-world evidence, focused on oncology EHR-derived data and analytics for biopharma and providers. It is highly comparable to Aetion because both build RWE platforms from real-world clinical data to support drug development and regulatory submissions for life sciences customers.
  • TriNetX: TriNetX operates a global health research network and RWE platform for clinical trial design, cohort identification, and real-world evidence studies. It is directly comparable to Aetion because both sell RWE platforms to biopharma for protocol design, regulatory evidence, and clinical development decisions using federated real-world data.

Emerging players

  • ConcertAI: ConcertAI provides AI-powered real-world evidence and data solutions with a focus on oncology and specialty therapeutics. It is comparable to Aetion because both serve biopharma with RWE analytics derived from clinical real-world data, competing for similar evidence-generation engagements with major pharma.
  • Health Catalyst: Health Catalyst provides healthcare data and analytics infrastructure, including life sciences solutions leveraging clinical and claims data. It is comparable to Aetion because both turn real-world clinical data into analytics products for healthcare stakeholders, though Health Catalyst is more provider-system-anchored while Aetion is biopharma-focused.
  • Tempus Labs: Tempus combines multimodal real-world data (omics, EHR, imaging) with AI to support biopharma research and clinical decision-making. It is comparable to Aetion because both build AI-enabled RWE platforms serving biopharma drug development, though Tempus is more focused on oncology and molecular data depth.
  • OM1: OM1 is a specialty real-world evidence and outcomes analytics company focused on chronic and specialty disease areas. It is comparable to Aetion because both deliver RWE analytics to biopharma and payers, with similar specialty-therapeutic-area orientation and emphasis on regulatory-grade evidence generation.

Broad incumbents

  • ICON plc: ICON (following its PRA Health Sciences acquisition) is a top global CRO with established real-world evidence and outcomes research capabilities. It is comparable to Aetion because both deliver RWE services to biopharma for clinical and post-marketing evidence generation, though ICON operates a much broader CRO service portfolio.
  • IQVIA: IQVIA is the largest global CRO and a leading provider of real-world evidence solutions to biopharma. It is comparable to Aetion because both serve major biopharma customers with RWE analytics, though IQVIA operates at vastly greater scale and offers a much broader portfolio spanning clinical trials, commercial, and real-world data.
  • Optum Life Sciences (UnitedHealth Group): Optum Life Sciences, part of UnitedHealth Group, provides real-world data and evidence solutions to biopharma leveraging one of the largest U.S. claims and EHR data assets. It is comparable to Aetion because both deliver RWE analytics for biopharma, though Optum's data scale and integrated payer-provider footprint are far larger.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Aetion social profiles

Digital presence

Aetion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aetion leadership team

Management profile

Number of profiles

Profiles14 records

Aetion funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aetion M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aetion

What does Aetion do?

Aetion develops and sells the Aetion Evidence Platform, a real-world evidence (RWE) analytics software platform used by major biopharma companies to analyze real-world data for drug development, clinical trial design, regulatory submissions, and personalized medicine. The platform leverages generative AI on Amazon Bedrock to translate scientific intent into analytical results, and is sold as enterprise SaaS with an option to procure through AWS Marketplace.

Is Aetion a public or private company?

Aetion is a private company. It is classified as corporate owned and is currently acquired.

When was Aetion founded?

Aetion was founded in 2012. It employs 51 to 100 people.

Where is Aetion based?

Aetion is headquartered in New York, United States, in the North America region.

How does Aetion make money?

One revenue line is on record: evidence Platform SaaS Subscription.

Who are Aetion's main competitors?

Direct peers on record are Evidera (PPD / Thermo Fisher Scientific), Flatiron Health and TriNetX. Emerging players are ConcertAI, Health Catalyst, Tempus Labs and OM1. Broad incumbents are ICON plc, IQVIA and Optum Life Sciences (UnitedHealth Group).

Does Aetion have an API?

No public API is recorded for Aetion.

What industry is Aetion in?

Aetion's product category is Healthcare Analytics Software. Its primary akta.pro industry code is BPAHALAN, Healthcare Outcomes & Real-World Evidence (RWE) Analytics, with a secondary code of HLACAOAM, Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireReal World Evidence Solutions Market worth $12.44 billion by 2031 - Exclusive Report by MarketsandMarkets™The real-world evidence solutions market is projected to grow from $6.22 billion in 2026 to $12.44 billion by 2031, a 14.9% CAGR. North America held the largest regional share at 58.3% in 2025, and the data sets segment is expected to grow fastest. Growth is driven by value-based care and FDA RWE submissions.EIN PresswireReal World Evidence Solutions Market Competitive Analysis: Trends, Leaders, and Strategic MovesThis article presents a competitive analysis of the Real World Evidence Solutions market, reporting that the top 10 players collectively held only 10% of total market revenue in 2024, indicating a fragmented market with moderate entry barriers. IQVIA Holdings Inc. led global sales in 2024 with approximately 1% market share, alongside nine other major players each holding around 1% share. Key competitive trends include the adoption of low-code workflow tools and integrated analytics platforms, with Aetion launching aetion activate in August 2025 to accelerate real-world data analysis.EIN PresswireReal World Evidence Solutions Market Competitive Analysis: Trends, Leaders, and Strategic MovesIQVIA Holdings Inc. led global sales in 2024 with a 1% market share in the real world evidence solutions market. The top 10 players accounted for 10% of total market revenue, reflecting moderate concentration. Low-code workflow tools and AI-driven analytics are key competitive trends.FinSMEsDatavant Completes Acquisition of AetionDatavant completed the acquisition of Aetion, a real-world evidence platform, with the deal amount undisclosed. Aetion joins Datavant's Life Sciences business, combining over 300 data partners across healthcare datasets. The acquisition aims to provide an end-to-end platform for data feasibility and analysis.citybizDatavant Acquires NEA-Backed AetionDatavant completed its acquisition of Aetion, a real-world evidence platform, adding it to its Life Sciences business. The combined ecosystem includes over 300 data partners across healthcare datasets. Datavant aims to deliver an end-to-end platform for data feasibility and analysis.AxiosDatavant's acquisition of Aetion worth nearly $400MDatavant, a New Mountain-backed health tech company, is acquiring Aetion in a deal valued at nearly $400 million, according to two sources familiar with the situation. The acquisition positions Datavant as a potential near-term exit candidate in the view of industry observers. This transaction represents a significant consolidation in the health tech data analytics sector.HIT ConsultantDatavant to Acquire Real-World Evidence Platform AetionDatavant announced an agreement to acquire Aetion, a real-world evidence platform, to create an end-to-end RWE platform. The combined entity will offer data discovery, linkage, privacy, and analytics, with Aetion's Activate software launched. The acquisition builds on Datavant's AWS Clean Rooms and aims to support FDA and EMA standards.AetionDatavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected DataDatavant announced it has signed an agreement to acquire Aetion, a real-world evidence platform. The combination will create an end-to-end RWE platform covering data discovery, linkage, privacy, curation, and advanced analysis. The companies will have a combined ecosystem of over 300 data partners.Business Wire BlogDatavant to Acquire Aetion, Empowering Healthcare and Life Sciences Organizations to Generate High-Quality, Scalable Real-World Evidence from Connected, Privacy-Protected DataDatavant announced it has signed an agreement to acquire Aetion, a real-world evidence platform. The combined companies will offer an end-to-end RWE platform with over 300 data partners. Aetion's Evidence Platform is available in AWS Marketplace, and Aetion Activate was launched.TmcnetAetion Launches Aetion® Evidence Platform Availability in AWS Marketplace, Accelerating Real-World Evidence Benefits for its CustomersAetion announced its Evidence Platform is now available in AWS Marketplace, enabling life sciences organizations to deploy real-world evidence analytics. The platform integrates AWS services like Amazon Bedrock for AI/ML, and offers seamless procurement, scalability, and compliance with HIPAA, GDPR, and 21 CFR Part 11.